Pollera C F, Conti E M, De Nigris A, Calabresi F
Oncology. 1987;44(2):73-7. doi: 10.1159/000226448.
To better define the dose-response relationship of moderate-dose (MD) metoclopramide (MCP), 42 patients receiving their first course of cisplatin (50 mg/m2) were randomly allocated to receive a short-course regimen of MCP, either at 1 mg/kg X 1 dose, 30 min before cisplatin (regimen A) or 1 mg/kg X 2 doses, 30 min before and 1 h after cisplatin (regimen B). The antiemetic response was assessed only by objective means (duration and volume of emesis over a 6-hour period). The results obtained in the two groups show a significantly better antiemetic effect (p = 0.03) employing the higher dose of this short-course regimen, with as much as 76% of the patients experiencing no vomiting or only a low degree of emesis. Furthermore, the lower-dose MCP regimen seems to be inadequate for preventing emesis, especially in the subgroups at higher emetic risk (patients with prior chemotherapy exposure and those concurrently receiving adriamycin. No significant side effects were present with either treatment. Further studies are required to define the best short-course regimen of MCP for patients receiving MD cisplatin.
为了更好地明确中等剂量甲氧氯普胺（MCP）的剂量 - 反应关系，42例接受顺铂（50mg/m²）首程治疗的患者被随机分配接受MCP短程方案，要么在顺铂给药前30分钟给予1mg/kg单次剂量（方案A），要么在顺铂给药前30分钟和给药后1小时给予1mg/kg两次剂量（方案B）。仅通过客观指标（6小时内呕吐的持续时间和量）评估止吐反应。两组结果显示，采用该短程方案的较高剂量时，止吐效果显著更好（p = 0.03），高达76%的患者未出现呕吐或仅出现轻度呕吐。此外，较低剂量的MCP方案似乎不足以预防呕吐，尤其是在呕吐风险较高的亚组中（既往接受过化疗的患者以及同时接受阿霉素治疗的患者）。两种治疗均未出现明显副作用。需要进一步研究来确定接受中等剂量顺铂治疗的患者最佳的MCP短程方案。
